In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on BioNano Genomics (BNGO – Research Report), with a price target of $2.00. The company’s shares closed yesterday at $0.70.
According to TipRanks, Massaro is an analyst with an average return of -7.9% and a 37.85% success rate. Massaro covers the Healthcare sector, focusing on stocks such as NeoGenomics, CareDx, and BioNano Genomics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioNano Genomics with a $2.67 average price target, which is a 281.43% upside from current levels. In a report released on May 10, Maxim Group also maintained a Buy rating on the stock with a $3.00 price target.
See today’s best-performing stocks on TipRanks >>
BNGO market cap is currently $201.2M and has a P/E ratio of -1.47.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BNGO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.
Read More on BNGO:
- Bionano Reports First Quarter 2023 Results and Highlights Recent Business Progress
- Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal
- Largest borrow rate increases among liquid names
- Bionano Genomics announces three publications on OGM
- UPDATE – Bionano Announces Preliminary Q1 2023 Results and Business Updates
